bpc-157 fda approved 2025 Is Legal in 2026? Compounding Status Explained fda bpc-157 ineligible for compounding
Description
While not yet FDA-approved as a standalone agent, cagrilintide peptide therapy is being investigated for: Obesity treatment Metabolic syndrome management Adjunctive therapy for GLP-1 agonist non-responders Research in combination with emerging agents like retatrutide Note: As of 2025, cagrilintide is still considered a research compound in many jurisdictions
It's going to change everything
The 28-day BUD allows a full research cycle from one vial
BPC-157 has shown protection against degenerative joint changes, while TB-500 improves cell migration and reduces fibrosis
